Trials / Completed

CompletedNCT00547586

Study Evaluating Oral MOA-728 For The Treatment Of OIBD In Subjects With Chronic Non-Malignant Pain

A Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel-Group Study of Oral MOA-728 for the Treatment of Opioid- Induced Bowel Dysfunction in Subjects With Chronic Nonmalignant Pain

Status: Completed
Phase: Phase 2
Study type: Interventional
Enrollment: 122 (actual)

Sponsor: Bausch Health Americas, Inc. · Industry
Sex: All
Age: 18 Years
Healthy volunteers: Not accepted

Summary

The primary purpose of this study is to evaluate the safety and dose-response relationship of N-methylnaltrexone bromide (MOA-728) by observing spontaneous bowel movements in subjects with chronic pain, which is not due to malignant cancer, and who have opioid-induced bowel dysfunction (OIBD).

Conditions

Constipation

Interventions

Type	Name	Description
DRUG	N-methylnaltrexone bromide (MOA-728)	Oral
OTHER	placebo	placebo

Timeline

Start date: 2007-10-01
Primary completion: 2008-02-01
Completion: 2008-02-01
First posted: 2007-10-22
Last updated: 2020-08-20
Results posted: 2020-08-20

Locations

41 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00547586. Inclusion in this directory is not an endorsement.